Assuming approval of the IND by the Center for Biologics Evaluation and Research at the FDA, RNL BIO plans to initiate its double-blinded, randomized, positive-control Phase II clinical trial during the third quarter of 2013 in Sugarland, acted as reviewers and completed revision of the protocol now under evaluation by the FDA.
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/RNL-BIO-Co-Ltd-Files-IND-To-Commence-Phase-II-Clin/ArticleNewsFeed/Article/detail/812244?ref=25
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/RNL-BIO-Co-Ltd-Files-IND-To-Commence-Phase-II-Clin/ArticleNewsFeed/Article/detail/812244?ref=25
No comments:
Post a Comment